Published in BJU Int on December 13, 2015
Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients. Int J Mol Sci (2016) 0.76
Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy. Cancer Res Treat (2016) 0.75
Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.75
Pazopanib: a Review in Advanced Renal Cell Carcinoma. Target Oncol (2017) 0.75
Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. Front Pharmacol (2017) 0.75
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol (1999) 8.46
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol (2005) 3.49
Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer (2011) 1.80
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Med Oncol (2012) 1.00
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer (2013) 0.99
Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol (2011) 0.93
First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. Clin Genitourin Cancer (2014) 0.92
Treatment of brain metastases from renal cell cancer. Urol Oncol (2009) 0.90
Brain metastasis from renal cell carcinoma. Prog Neurol Surg (2012) 0.87
Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol (2014) 2.32
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol (2016) 0.82
Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol (2015) 0.81
Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Mod Pathol (2015) 0.81
Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. Psychooncology (2015) 0.78
Proteinuria with first-line therapy of metastatic renal cell cancer. J Oncol Pharm Pract (2014) 0.76
Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psychooncology (2016) 0.75
Key considerations in the treatment of von Hippel-Lindau disease. Future Oncol (2016) 0.75
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. Cancer Treat Rev (2020) 0.75
Incidence, clinicopathologic features, and fusion transcript landscape of translocation renal cell carcinomas. Histopathology (2017) 0.75